A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer

Oncology

Volumn 66, Issue 3, 2004, Pages 192-196

  Agelaki, Sofia ^a   Syrigos, Kostas ^b   Christophylakis, Charalambos ^c   Boukovinas, John ^d   Varthalitis, John ^e   Pavlakou, Georgia ^f   Athanasiadis, Athanasios ^g   Kouroussis, Charalambos ^a   Vardakis, Nikolaos ^a   Maltezakis, George ^a   Milaki, Georgia ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c 401 Military Hospital of Athens   (Greece)

^d THEAGENIO CANCER HOSPITAL   (Greece)

^e Agios Georgios General Hospital of Chania   (Greece)

^f SOTIRIA GENERAL HOSPITAL   (Greece)

^g GENERAL HOSPITAL   (Greece)

Author keywords

Gemcitabine; Irinotecan (CPT 11); Pretreated small cell lung cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG EDEMA; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 3042538088     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077994     Document Type: Article

References (22)

1. Ihde DC, Glatstein E, Pass HI: in: DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 911-950.
2. Ebi N, Kubota K, Nishiwaki Y, Hoho F, Matsumoto T, Kakimura R, Ohmatsu H, Sekine I, Yokosaki M, Gotoh K, Yamamoto H, Kodama T: Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997;27:166-169.
3. Zochbauer-Müller S, Pirker R, Huber H: Treatment of small cell lung cancer patients. Ann Oncol 1999;10(suppl 6):83-91.
4. Le Chevalier T, Ibrahim N, Chomy P, Rivière A, Monier A, Magherini E, Pujol JL: A phase II study of irinotecan (CPT-11) in patients with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT). Proc Am Soc Clin Oncol 1997;16:450.
5. DeVore RF, Blanke CD, Denham CA, Hainsworth JD, Gralla RJ, Koletsky AJ, Savaraj N, Vogel CL, Sarna GP, Brooks DJ, Petit RG, Elfring GL, Schaaf LJ, Hanover CK, Miller LL: Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1998;17:451.
6. Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, Motomiya M, Kurita Y, Hasegawa K, Kuriyama T: A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho 1991;18:1013-1019.
7. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Tanaka M: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-1229.
8. Fujita A, Takabatake H, Tagaki S, Sekine K: Pilot study of irinotecan in refractory small cell lung cancer. Gan To Kagaku Ryoho 1995;22:889-893.
9. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
10. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994;5:283-285.
11. Masters GA, DeClerk L, Blanke C, Sandler A, DeVore R, Miller K, Johnson D Phase II trial of gemcitabine in refractory or relapsed small cell lung cancer. Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003;21:1550-1555.
12. van der Lee I, Smit EF, van Putten JW, Groen HJ, Schlosser NJ, Postmus PE, Schramel FM: Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001;12:557-561.
13. Bahadori HR, Rocha Lima CM, Green MR, Safa AR: Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999;19:5423-5428.
14. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapy agent. J Chronic Dis 1961;13:346-353.
15. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A: Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987; 23:1697-1699.
16. Vincent M, Evans B, Smith I: First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988;21:45-48.
17. Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC: Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatinresistant small cell lung cancer. Cancer Treat Rep 1987;71:941-945.
18. Albain KS, Crowley JJ, Hutchins L, Gandara D, O'Bryan RM, Von Hoff DD, Griffin B, Livingston RB: Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 1993;72:1184-1191.
19. Masuda N, Matsui K, Negoro S, et al: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998;16:3329-3334.
20. Naka N, Kawahara M, Okishio K, et al: Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002;37:319-323.
21. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
22. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-2096.